The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS): A Pragmatic Trial of Precision Prostate Cancer Screening

Status: Recruiting
Location: See location...
Intervention Type: Other, Genetic
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might help identify which men are at highest risk for prostate cancer. This study will examine whether a genetic test helps identify men at risk for significant prostate cancer while helping men who are at low risk for prostate cancer avoid unnecessary biopsies. If this genetic test proves beneficial, it will improve the way that healthcare providers screen male Veterans for prostate cancer.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 55
Maximum Age: 69
Healthy Volunteers: t
View:

• baseline age 55-69 years

• receipt of regular VA care

• Veteran status

Locations
United States
Massachusetts
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
RECRUITING
Boston
Contact Information
Primary
Charles A Brunette, PhD
charles.brunette@va.gov
(857) 364-6324
Time Frame
Start Date: 2024-02-01
Estimated Completion Date: 2030-09-30
Participants
Target number of participants: 5000
Treatments
Experimental: Precision screening intervention
The precision screening intervention will consist of an interpreted prostate cancer genetic risk assessment (GRA) report, provided to the participant along with tailored prostate cancer screening recommendations and, in cases of high genetic risk, genetic counseling. The risk report and supporting educational materials will also be provided to the participant's primary care provider. Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
Experimental: Usual care
Usual care in this study includes receipt of a brief brochure about shared decision-making in prostate cancer screening.
Related Therapeutic Areas
Sponsors
Leads: VA Office of Research and Development

This content was sourced from clinicaltrials.gov